Interim Policy on Compounding Using Bulk Drug Substances Under Section 503B of the Federal Food, Drug, and Cosmetic Act
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
January 6, 2025
January 7, 2025
eabbf240-5386-496d-ad18-2d7246237567
Related Documents
Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the Federal Food, Drug, and Cosmetic Act
Guidance DocumentJanuary 6, 2025Center for Drug Evaluation and Research
Evaluation of Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act
Guidance DocumentMarch 13, 2019Center for Drug Evaluation and Research
Adverse Event Reporting for Outsourcing Facilities Under Section 503B of the Federal Food, Drug, and Cosmetic Act
Guidance DocumentOctober 8, 2015Center for Drug Evaluation and Research
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Subscribe to our newsletter
Get the latest updates and insights delivered to your inbox